E. L. Kwak

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

Gerald M. Edelman, Cindi Bedell, Geoffrey I. Shapiro et al. · Journal of Clinical Oncology · 2010 · 77 citations

Lymphoid Neoplasia, Oncology, Medicine +13

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

Weiwei Tan, Keith D. Wilner, Y. Bang et al. · Journal of Clinical Oncology · 2010 · 46 citations

Pharmacotherapy, Cancer Patients, Metronomic Chemotherapy +17

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

Geoffrey I. Shapiro, P. LoRusso, E. L. Kwak et al. · Journal of Clinical Oncology · 2011 · 44 citations

Pathology, Pi3k/akt Signaling Pathways, Pi3k Inhibitor +17

G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066

E. L. Kwak, D. Ross Camidge, JeVrey W. Clark et al. · European Journal of Cancer Supplements · 2009 · 22 citations

Molecular Pharmacology, Escalation Trial, Oncology +9

A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

J. M. Cleary, Elisabeth I. Heath, E. L. Kwak et al. · Journal of Clinical Oncology · 2010 · 20 citations

Solid Tumors, Cancer Management, Next-generation Hsp90 Inhibitor +20